Affymax(R) Highlights Upcoming Hematide(TM) Data Presentations at the American Society of Nephrology Renal Week 2007.PALO ALTO, Calif. -- Affymax, Inc. (Nasdaq: AFFY) today announced that several presentations featuring Hematide, the company's lead product candidate in development globally with Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited (武田薬品工業株式会社 Limited for the treatment of anemia, will be presented at the American Society of Nephrology Renal Week 2007 in San Francisco between October 31 - November 5, 2007. The three data presentations include results of the use of Hematide[TM] to treat anemia in chronic kidney disease Chronic kidney disease (CKD), also know as chronic renal disease, is a progressive loss of renal function over a period of months or years through five stages. Each stage is a progression through an abnormally low and progressively worse glomerular filtration rate, which is (CKD See count-key-data. ) patients on dialysis, results of Hematide in CKD patients in the predialysis setting, and a study of Hematide to treat pure red cell aplasia pure red cell aplasia Hematology A type of anemia caused by selective depletion of erythroid cells Pure red cell aplasia types Acute (PRCA PRCA Professional Rodeo Cowboys Association PRCA Pure Red-Cell Aplasia PRCA Public Relations Consultants Association PrCa Prostate Cancer PRCA Proportional Rate-Control Algorithm PRCA Personal Report of Communication Apprehension ). This study on PRCA will be presented at an oral presentation session by Iain C. Macdougall, M.D., Hematide clinical trial investigator, consultant nephrologist and honorary senior lecturer in the Department of Renal Medicine at King's College Hospital King's College Hospital is a primary care facility in the London Borough of Lambeth, referred to locally and by staff simply as "King's" or abbreviated internally to "KCH". It serves an inner city population of 700,000 in the London boroughs of Lambeth, Southwark and Lewisham. in London. PRCA, a rare autoimmune disorder, occurs when the body produces neutralizing antibodies to recombinant human erythropoietin (EPO EPO see erythropoietin. EPO Erythropoietin, see there ), thus suppressing the production of red blood cells Red blood cells Cells that carry hemoglobin (the molecule that transports oxygen) and help remove wastes from tissues throughout the body. Mentioned in: Bone Marrow Transplantation red blood cells by the bone marrow. "Treatment of Erythropoietin Antibody-Mediated Pure Red Cell Aplasia with a Novel Synthetic Peptide-based Erythropoietin Receptor Agonist" Abstract #SU-FC061 (Sunday, November 4, 4:00 p.m. - 6:00 p.m. during the "Anemia in CKD: Mechanisms and Therapy" session, Oral Presentation, Room 2018 of the Moscone Center) "Comparison of Monthly Dosing Schemes Using Hematide, a Synthetic Peptide-based Erythropoiesis erythropoiesis /eryth·ro·poi·e·sis/ (-poi-e´sis) the formation of erythrocytes.erythropoiet´ic e·ryth·ro·poi·e·sis n. The formation or production of red blood cells. Stimulating Agent (ESA), to Maintain Hemoglobin (Hb) in Hemodialysis (HD) Patients Previously Treated with Epoetin Alfa (EPO)" Abstract #SU-PO783 (Saturday, November 3, 11:00 a.m. to noon, Poster Presentation, Exhibit Hall) "Comparison of Monthly Dosing Schemes Using Hematide, a Synthetic Peptide-based Erythropoiesis Stimulating Agent (ESA), to Correct Anemia in Patients with Chronic Kidney Disease (CKD) not on Dialysis" Abstract #SA-PO777 (Sunday, November 4, 11:00 a.m. to noon, Poster Presentation, Exhibit Hall) About Hematide Hematide is a novel synthetic, pegylated peptidic compound that binds to and activates the erythropoietin receptor and thus acts as an erythropoiesis stimulating agent. The product is being developed for treatment of anemia in patients with chronic renal failure chronic renal failure Chronic kidney failure Nephrology A slow decline in renal function, which may be 2º to chronic HTN, DM, CHF, SLE, or sickle cell anemia and, if extreme, leads to ESRD, mandating kidney dialysis; an abrupt decline in renal function may be and cancer patients receiving chemotherapy. About Affymax, Inc. Affymax, Inc. is a biopharmaceutical company developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax's lead product candidate, Hematide[TM], is currently in Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. stage for the treatment of anemia associated with chronic renal failure and in clinical trials for the treatment of anemia in cancer patients. For additional information, please visit www.affymax.com. About Takeda Located in Osaka, Japan, Takeda (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, www.takeda.com. This release contains forward-looking statements, including statements regarding the timing, design and results of the Company's clinical trials and drug development program and the timing and likelihood of the commercialization of Hematide. The Company's actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties, including risks relating to the continued safety and efficacy of Hematide in clinical development, the potential for once per month dosing, regulatory requirements and approvals, research and development efforts, industry and competitive environment, intellectual property rights and disputes and other matters that are described in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement in this press release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion